Veristat expands into Europe with Spero Oncology acquisition

Published: 3-May-2016

US CRO now offers full clinical operations support in Europe


Veristat, a US-based clinical research organisation (CRO), is expanding its clinical research offerings into Europe through the acquisition of UK-based Spero Oncology for an undisclosed sum.

Spero Oncology provides clinical operations support for oncology clinical trials primarily in Europe, but also in Australia and New Zealand.

With the deal, Veristat now offers full clinical operations support in Europe, including feasibility studies, legal representation in the EU, clinical monitoring, project management, protocol writing and regulatory strategy.

Patrick Flanagan, Chief Executive of Veristat, said the acquisition was an important milestone for the firm.

'Adding the Spero Oncology team to Veristat will strengthen our ability to deliver value to our clients’ multi-national trials throughout North America and Europe,' he said.

'We feel that this team is a great fit culturally and professionally and will enhance our ability to make a difference in the trials we perform on behalf of sponsors.'

Spero Oncology will immediately be integrated and operate under the Veristat brand and name.

Veristat has appointed Spero’s founder and Managing Director, Theresa Bruce, to the newly created position of Vice President of Clinical Operations. She joins Veristat with more than 23 years of clinical research experience in both the pharmaceutical and CRO industry. She has spent the last 16 years providing leadership and project management support for numerous oncology trials. Prior to founding Spero Oncology, she was the COO of Nexus Oncology.

You may also like